exploring frontiers of bioscience

The Paul G. Allen Frontiers Group explores the landscape of science to identify and invest in pioneers with ideas that will create new knowledge and make the world better. Through continuous dialogue with scientists and visionaries around the world, the Frontiers Group will uncover novel ideas in bioscience with the potential to transform fields.  The Frontiers Group will help to create new ways of doing science, new ways of solving problems, and foster a creative community that imagines and creates the future.

Landscape perspective

We engage with scientists and visionaries around the world to uncover and make visible emerging frontiers and new directions in science. We convene creative partners in novel ways to imagine possible futures.

Funding new ideas

We invest in investigators and centers for frontier explorations that lead to new fundamental insights and produce important solutions with big impact.

Creative synthesis

We link ideas across the landscape of quantitative fields now addressing bioscience research and seek out creative approaches that span disciplines.

Current funding opportunities

The Paul G. Allen Frontiers Group seeks to select investigators to pursue pioneering research that opens new directions and answers broad scientific questions. We request letters of intent for proposals focusing on in vivo epigenetic editing, assessment and visualization--approaches to enable capabilities that currently are not possible. There will be up to three awards made, and awards are anticipated to range from $1-1.5M in total funding over three years.

Learn more about our programs and funding, and read the request for proposals.

Allen Distinguished Investigators

Michael Elowitz | Innovator

November 22, 2016

Allen Distinguished Investigator Michael Elowitz is developing a unique platform to investigate how cells in an embryo diversify into many distinct cell types.

Request for Proposals

Request for Proposals: Epigenetics

November 28, 2016

We request letters of intent for proposals focusing on in vivo epigenetic editing, assessment and visualization technology development. There will be up to 3 awards made, and awards are anticipated to range from $1-1.5M in total funding over three years.

Director's Blog

Far from the Crowd

Tom Skalak

October 3, 2016

October’s new Nobel Prize in Medicine or Physiology was awarded to a deserving pioneer, Dr. Yoshinori Ohsumi, for his work to describe the process of autophagy – the removal of cellular debris, which is essential as human beings and other living organisms replenish our tissues throughout our lives. Dr. Ohsumi’s original research is an inspiring example illustrating why support of true pioneers, people with the intellectual courage and creativity to head in new directions, is essential to scientific progress.